Production & Sales

Bristol-Myers’ opdivo approved in Europe for urothelial carcinoma

Bristol-Myers Squibb’s Opdivo (nivolumab) has been approved by the European Commission (EC) for the treatment of locally advanced unresectable or metastatic urothelial carcinoma (mUC) in adults after failure of prior platinum-based therapy.

Roquette to acquire Brazilian pharmaceutical tablet maker Itacel

Plant-based ingredient manufacturer Roquette has agreed to buy Brazilian pharmaceutical tablet maker Itacel.

Abzena signs antibody manufacturing development deal with University College London

Abzena has entered into a manufacturing agreement with University College London (UCL).

Arix Bioscience raises £100m in IPO

Global healthcare and life science company Arix Bioscience has raised £100m in its Initial Public Offering (IPO) on the main market of the London Stock Exchange.

Takeda acquires Ariad Pharmaceuticals

Takeda Pharmaceutical has completed its acquisition of Ariad Pharmaceuticals for $24.00 per share in cash.

Sanofi agrees to divest five OTC products to Ipsen for EUR83m

Sanofi has agreed to divest five of its over-the-counter consumer healthcare products in Europe to French pharma firm Ipsen for €83m.

Reckitt Benckiser to purchase Mead Johnson for $16.6bn

Reckitt Benckiser (RB) has agreed to acquire Mead Johnson Nutrition for $90 in cash for each share of common stock, valuing the total equity at $16.6bn.

Arven selects GE Healthcare’s manufacturing platform to expand production capacity at Turkish facility

GE Healthcare’s FlexFactory manufacturing platform has been selected to expand production capacity at Arven Pharmaceuticals' facility in Kirklareli, Turkey.

Takeda to buy Ariad Pharmaceuticals for $5.2bn

Japan's Takeda Pharmaceutical has agreed to acquire US cancer drug maker Ariad Pharmaceuticals in a transaction worth about $5.2bn.